If the efficacy of axitinib can be observed, it should be used until unacceptable toxicity occurs before discontinuation is considered, so its dosing regimen varies from person to person. Axitinib is used clinically in adult patients with progressive renal cell carcinoma who have failed prior treatment with a tyrosine kinase inhibitor or cytokine. As long as the drug is observed to be beneficial to the patient, it should be kept on until intolerable side effects occur and then discontinuation should be considered. The duration of the medication varies for each individual as their specific condition and constitution are different and should not be generalized. Adverse effects of this product include diarrhea, high blood pressure, loss of appetite, fatigue, nausea, vomiting, headache, cough, etc. It is contraindicated for those who are allergic to Axitinib. Please adhere to the medication according to the doctor’s instructions, and regularly go to the hospital to review the condition, do not stop the drug on your own, so as not to delay the condition.